{"id":22237,"date":"2025-12-10T12:36:15","date_gmt":"2025-12-10T10:36:15","guid":{"rendered":"https:\/\/www.kapa3.gr\/?p=22237"},"modified":"2025-12-10T13:14:05","modified_gmt":"2025-12-10T11:14:05","slug":"gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows","status":"publish","type":"post","link":"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/","title":{"rendered":"GD2: A Critical Biomarker and Therapeutic Target \u2013 What the Latest Evidence Shows"},"content":{"rendered":"<p><strong>New scientific data highlight GD2 \u2014 a glycolipid biomarker expressed in specific cancer cells \u2014 as one of the most promising therapeutic targets in modern oncology<\/strong>. A recent review published in an international scientific journal brings together the latest findings on the use of GD2 in immunotherapies, CAR-T cell treatments, monoclonal antibodies, and other innovative approaches.<\/p>\n<p><strong>What is GD2 and why does it matter?<\/strong><\/p>\n<p>GD2 is a molecule known as disialoganglioside-2, found in high concentrations on the surface of certain cancer cells. This makes it particularly valuable as a target for personalized immunotherapies, as treatments can \u201crecognize\u201d and destroy GD2-positive cells while sparing healthy tissues.<\/p>\n<p>Cancers with high GD2 expression include:<br \/>\n<strong>\u2022 Neuroblastoma<\/strong><br \/>\n<strong>\u2022 Osteosarcoma<\/strong><br \/>\n<strong>\u2022 Melanoma<\/strong><br \/>\n<strong>\u2022 Breast cancer (triple-negative in some cases)<\/strong><br \/>\n<strong>\u2022 Certain lung cancers<\/strong><br \/>\n<strong>\u2022 Rare pediatric tumors<\/strong><\/p>\n<p>In <strong>neuroblastoma<\/strong> \u2014 one of the most common pediatric cancers \u2014 GD2-directed antibody therapy has already improved survival in high-risk patients.<\/p>\n<p><strong>The new scientific review<\/strong> maps the current progress in GD2-targeted therapies, highlighting the technologies showing the strongest clinical potential. GD2-directed monoclonal antibodies, already effective in children with neuroblastoma, are evolving into more precise and safer versions, aiming to expand their use in adult tumors as well. The review also presents updated data from clinical trials of GD2-directed CAR-T cells: despite challenges such as toxicity, tumor escape, and limited persistence, <strong>newer CAR-T generations demonstrate improved safety, deeper penetration into solid tumors, and especially promising outcomes in pediatric patients.<\/strong><\/p>\n<p>The review further examines combination immunotherapies that pair GD2 targeting with radiotherapy, chemotherapy, or immune checkpoint inhibitors, offering enhanced effectiveness against resistant tumors. Finally, emerging platforms are described \u2014 including bispecific antibodies, \u201csmart\u201d nanoparticle-based strategies, and drug-delivery technologies that target only GD2-positive cells \u2014 expanding the therapeutic landscape and opening new avenues for future applications.<\/p>\n<p><strong>What does this mean for patients?<\/strong><\/p>\n<p>GD2-targeted therapy is no longer theoretical \u2014 it is already a reality in certain pediatric cancers and is rapidly expanding into other tumor types.<\/p>\n<p>Key benefits for patients include:<br \/>\n\u2022 greater precision with reduced toxicity<br \/>\n\u2022 the potential for highly individualized treatment based on tumor profile<br \/>\n\u2022 new hope for tumors that remain difficult to treat with existing methods<br \/>\n\u2022 improved survival prospects, especially for children<\/p>\n<p>For pediatric and young adult patients \u2014 a group with historically limited and often highly burdensome treatment options \u2014 GD2-directed therapies represent a significant step forward.<\/p>\n<p>Despite the important progress made, several challenges remain. These include side effects such as neuropathic pain, tumor resistance or escape from targeting, the high cost and limited availability of advanced treatments, and the need for large, multi-center clinical trials to produce more robust and generalizable data. Still, research activity is intensifying, with dozens of clinical studies currently ongoing worldwide.<\/p>\n<p>Within this evolving landscape, <strong>Kapa3<\/strong> remains committed to providing accurate, accessible, and compassionate information to patients and families, particularly those facing severe, rare, or pediatric cancers. Advances in GD2-targeted therapies are opening new pathways for children and young people with limited options today , showcasing the power and potential of immunotherapy. At the same time, they highlight the urgent need for equitable access to innovative treatments for patients in Greece.<\/p>\n<p><strong>Kapa3<\/strong> will continue to follow scientific developments closely and keep the community informed in a clear, reliable, and human-centered way.<\/p>\n<p>Sources: <a href=\"https:\/\/www.ejcancer.com\/article\/S0959-8049%2825%2900979-7\/fulltext\">Here<\/a><\/p>\n<p>Text\/Adaptation: Ifiyenia Anastasiou for Kapa3<\/p>\n","protected":false},"excerpt":{"rendered":"<p>New scientific data highlight GD2 \u2014 a glycolipid biomarker expressed in specific cancer cells \u2014 as one of the most promising therapeutic targets in modern oncology. A recent review published &hellip; <a href=\"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">GD2: A Critical Biomarker and Therapeutic Target \u2013 What the Latest Evidence Shows<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[218,631,1282,606,885,1278,716,704,588,604,688,1057,834,1283,1279,1280,1277,1281],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>GD2: New Advances in Targeted Cancer Therapies<\/title>\n<meta name=\"description\" content=\"GD2 is emerging as a key target in modern cancer therapy, with promising advances in immunotherapy and CAR-T approaches.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GD2: New Advances in Targeted Cancer Therapies\" \/>\n<meta property=\"og:description\" content=\"GD2 is emerging as a key target in modern cancer therapy, with promising advances in immunotherapy and CAR-T approaches.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/\" \/>\n<meta property=\"og:site_name\" content=\"K3\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapa3.k3\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-10T10:36:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-10T11:14:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.kapa3.gr\/wp-content\/uploads\/2021\/06\/kapa-3-social.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"k3-editor\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"k3-editor\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/\"},\"author\":{\"name\":\"k3-editor\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/#\/schema\/person\/bb0605d11e13832c0e59d34ad0afa9d0\"},\"headline\":\"GD2: A Critical Biomarker and Therapeutic Target \u2013 What the Latest Evidence Shows\",\"datePublished\":\"2025-12-10T10:36:15+00:00\",\"dateModified\":\"2025-12-10T11:14:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/\"},\"wordCount\":551,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/#organization\"},\"articleSection\":[\"CANCER\",\"Cancer Awareness\",\"cancer biomarkers\",\"Cancer Care\",\"cancer empowerment\",\"cancer immunotherapy\",\"cancer monitoring\",\"Cancer Patient Support\",\"cancer patients\",\"Cancer Policy\",\"cancer treatments\",\"Child health\",\"childhood cancer\",\"clinical research\",\"GD2 CAR-T cells\",\"GD2 neuroblastoma\",\"GD2 therapy\",\"innovative cancer therapies\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/\",\"url\":\"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/\",\"name\":\"GD2: New Advances in Targeted Cancer Therapies\",\"isPartOf\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/#website\"},\"datePublished\":\"2025-12-10T10:36:15+00:00\",\"dateModified\":\"2025-12-10T11:14:05+00:00\",\"description\":\"GD2 is emerging as a key target in modern cancer therapy, with promising advances in immunotherapy and CAR-T approaches.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.kapa3.gr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GD2: A Critical Biomarker and Therapeutic Target \u2013 What the Latest Evidence Shows\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/#website\",\"url\":\"https:\/\/www.kapa3.gr\/en\/\",\"name\":\"K3\",\"description\":\"\u039a\u0395\u039d\u03a4\u03a1\u039f \u039a\u0391\u0398\u039f\u0394\u0397\u0393\u0397\u03a3\u0397\u03a3 \u039a\u0391\u03a1\u039a\u0399\u039d\u039f\u03a0\u0391\u0398\u03a9\u039d\",\"publisher\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.kapa3.gr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/#organization\",\"name\":\"\u039a\u03ad\u03bd\u03c4\u03c1\u03bf \u039a\u03b1\u03b8\u03bf\u03b4\u03ae\u03b3\u03b7\u03c3\u03b7\u03c2 \u039a\u03b1\u03c1\u03ba\u03b9\u03bd\u03bf\u03c0\u03b1\u03b8\u03ce\u03bd (\u039a3)\",\"url\":\"https:\/\/www.kapa3.gr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.kapa3.gr\/wp-content\/uploads\/2020\/03\/Kapa3-logo.png\",\"contentUrl\":\"https:\/\/www.kapa3.gr\/wp-content\/uploads\/2020\/03\/Kapa3-logo.png\",\"width\":350,\"height\":111,\"caption\":\"\u039a\u03ad\u03bd\u03c4\u03c1\u03bf \u039a\u03b1\u03b8\u03bf\u03b4\u03ae\u03b3\u03b7\u03c3\u03b7\u03c2 \u039a\u03b1\u03c1\u03ba\u03b9\u03bd\u03bf\u03c0\u03b1\u03b8\u03ce\u03bd (\u039a3)\"},\"image\":{\"@id\":\"https:\/\/www.kapa3.gr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapa3.k3\",\"https:\/\/www.instagram.com\/kapa3.k3\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/#\/schema\/person\/bb0605d11e13832c0e59d34ad0afa9d0\",\"name\":\"k3-editor\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kapa3.gr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5838368fc27f3acabd32a77c8dff3dce?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5838368fc27f3acabd32a77c8dff3dce?s=96&d=mm&r=g\",\"caption\":\"k3-editor\"},\"url\":\"https:\/\/www.kapa3.gr\/en\/author\/k3-editor\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GD2: New Advances in Targeted Cancer Therapies","description":"GD2 is emerging as a key target in modern cancer therapy, with promising advances in immunotherapy and CAR-T approaches.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/","og_locale":"en_US","og_type":"article","og_title":"GD2: New Advances in Targeted Cancer Therapies","og_description":"GD2 is emerging as a key target in modern cancer therapy, with promising advances in immunotherapy and CAR-T approaches.","og_url":"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/","og_site_name":"K3","article_publisher":"https:\/\/www.facebook.com\/kapa3.k3","article_published_time":"2025-12-10T10:36:15+00:00","article_modified_time":"2025-12-10T11:14:05+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.kapa3.gr\/wp-content\/uploads\/2021\/06\/kapa-3-social.jpg","type":"image\/jpeg"}],"author":"k3-editor","twitter_card":"summary_large_image","twitter_misc":{"Written by":"k3-editor","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/#article","isPartOf":{"@id":"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/"},"author":{"name":"k3-editor","@id":"https:\/\/www.kapa3.gr\/en\/#\/schema\/person\/bb0605d11e13832c0e59d34ad0afa9d0"},"headline":"GD2: A Critical Biomarker and Therapeutic Target \u2013 What the Latest Evidence Shows","datePublished":"2025-12-10T10:36:15+00:00","dateModified":"2025-12-10T11:14:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/"},"wordCount":551,"commentCount":0,"publisher":{"@id":"https:\/\/www.kapa3.gr\/en\/#organization"},"articleSection":["CANCER","Cancer Awareness","cancer biomarkers","Cancer Care","cancer empowerment","cancer immunotherapy","cancer monitoring","Cancer Patient Support","cancer patients","Cancer Policy","cancer treatments","Child health","childhood cancer","clinical research","GD2 CAR-T cells","GD2 neuroblastoma","GD2 therapy","innovative cancer therapies"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/","url":"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/","name":"GD2: New Advances in Targeted Cancer Therapies","isPartOf":{"@id":"https:\/\/www.kapa3.gr\/en\/#website"},"datePublished":"2025-12-10T10:36:15+00:00","dateModified":"2025-12-10T11:14:05+00:00","description":"GD2 is emerging as a key target in modern cancer therapy, with promising advances in immunotherapy and CAR-T approaches.","breadcrumb":{"@id":"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kapa3.gr\/en\/gd2-a-critical-biomarker-and-therapeutic-target-what-the-latest-evidence-shows\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kapa3.gr\/en\/"},{"@type":"ListItem","position":2,"name":"GD2: A Critical Biomarker and Therapeutic Target \u2013 What the Latest Evidence Shows"}]},{"@type":"WebSite","@id":"https:\/\/www.kapa3.gr\/en\/#website","url":"https:\/\/www.kapa3.gr\/en\/","name":"K3","description":"\u039a\u0395\u039d\u03a4\u03a1\u039f \u039a\u0391\u0398\u039f\u0394\u0397\u0393\u0397\u03a3\u0397\u03a3 \u039a\u0391\u03a1\u039a\u0399\u039d\u039f\u03a0\u0391\u0398\u03a9\u039d","publisher":{"@id":"https:\/\/www.kapa3.gr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kapa3.gr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.kapa3.gr\/en\/#organization","name":"\u039a\u03ad\u03bd\u03c4\u03c1\u03bf \u039a\u03b1\u03b8\u03bf\u03b4\u03ae\u03b3\u03b7\u03c3\u03b7\u03c2 \u039a\u03b1\u03c1\u03ba\u03b9\u03bd\u03bf\u03c0\u03b1\u03b8\u03ce\u03bd (\u039a3)","url":"https:\/\/www.kapa3.gr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kapa3.gr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.kapa3.gr\/wp-content\/uploads\/2020\/03\/Kapa3-logo.png","contentUrl":"https:\/\/www.kapa3.gr\/wp-content\/uploads\/2020\/03\/Kapa3-logo.png","width":350,"height":111,"caption":"\u039a\u03ad\u03bd\u03c4\u03c1\u03bf \u039a\u03b1\u03b8\u03bf\u03b4\u03ae\u03b3\u03b7\u03c3\u03b7\u03c2 \u039a\u03b1\u03c1\u03ba\u03b9\u03bd\u03bf\u03c0\u03b1\u03b8\u03ce\u03bd (\u039a3)"},"image":{"@id":"https:\/\/www.kapa3.gr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapa3.k3","https:\/\/www.instagram.com\/kapa3.k3\/"]},{"@type":"Person","@id":"https:\/\/www.kapa3.gr\/en\/#\/schema\/person\/bb0605d11e13832c0e59d34ad0afa9d0","name":"k3-editor","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kapa3.gr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5838368fc27f3acabd32a77c8dff3dce?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5838368fc27f3acabd32a77c8dff3dce?s=96&d=mm&r=g","caption":"k3-editor"},"url":"https:\/\/www.kapa3.gr\/en\/author\/k3-editor\/"}]}},"_links":{"self":[{"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/posts\/22237"}],"collection":[{"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/comments?post=22237"}],"version-history":[{"count":2,"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/posts\/22237\/revisions"}],"predecessor-version":[{"id":22239,"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/posts\/22237\/revisions\/22239"}],"wp:attachment":[{"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/media?parent=22237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/categories?post=22237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.kapa3.gr\/en\/wp-json\/wp\/v2\/tags?post=22237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}